Negative data from lung cancer trial may change practice guidelines, study designs.

Journal of the National Cancer Institute

Volumn 98, Issue 21, 2006, Pages 1518-1520

  McNeil, Caroline ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; META ANALYSIS; METHODOLOGY; PATHOLOGY; PRACTICE GUIDELINE; STANDARD; SURVIVAL; TREATMENT FAILURE; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT FAILURE; UNITED STATES;

EID: 39049178207     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj459     Document Type: Article

References (0)